EICHORCondition: Multiple Myeloma · Sponsor: AbbVie
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM. Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 6 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants in substudies 1-4 will receive escalating doses of etentamig alone or with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R), followed by etentamig at the dose levels established during the escalation phases alone or with DR, Kd, R. Participants in substudies 1-4 can also receive daratumumab, lenalidomide and dexamethasone (DRd), R, or daratumumab, carfilzomib, and dexamethasone (DKd) as a comparator in the dose expansion phases. Participants in substudies 5-6 will receive escalating doses or at the dose levels established during the escalation phases of ABBV-2001 with iberdomide or mezigdomide. Around 602 adult participants with MM will be enrolled at approximately 75 sites worldwide In substudies 1-3, participants will receive escalating do…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Eastern cooperative oncology group (ECOG) performance of \<= 1. * Confirmed diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) diagnostic criteria with either newly diagnosed or relapsed or refractory (RR) MM, depending on the substudy. Exclusion Criteria: * Participant who has known active central nervous system involvement of MM. * Participant who has known active infection as outlined in the protocol.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| City of Hope National Medical Center /ID# 273132 | Duarte, California, United States | Recruiting |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911 | Irvine, California, United States | Recruiting |
| Colorado Blood Cancer Institute /ID# 273129 | Denver, Colorado, United States | Recruiting |
| Moffitt Cancer Center /ID# 272628 | Tampa, Florida, United States | Recruiting |
| Winship Cancer Institute of Emory University /ID# 274830 | Atlanta, Georgia, United States | Recruiting |
| Mount Sinai - The Tisch Cancer Institute /ID# 272470 | New York, New York, United States | Recruiting |
| Weill Cornell Medical College /ID# 272517 | New York, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill /ID# 274667 | Chapel Hill, North Carolina, United States | Recruiting |
| Atrium Health Levine Cancer Institute /ID# 276193 | Charlotte, North Carolina, United States | Recruiting |
| Atrium Health Wake Forest Baptist Medical Center /ID# 274847 | Winston-Salem, North Carolina, United States | Recruiting |
| Oncology Hematology Care - Blue Ash /ID# 272918 | Cincinnati, Ohio, United States | Recruiting |
| The Ohio State University /ID# 271336 | Columbus, Ohio, United States | Recruiting |
+ 22 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06892522